drugset / Trial / NCT02180204

Tenecteplase Versus Alteplase in Ischemic Stroke Management (TALISMAN)

NCT02180204

Phase 2/3 Withdrawn Reza Behrouz, DO
RandomizedParallel-groupDouble-blindTreatment

Summary

This is a double-blind parallel arm randomized trial aimed to assess efficacy and safety of intravenous Tenecteplase compared to intravenous Alteplase in eligible patients who present with symptoms of acute ischemic stroke within 3 to 4.5 hours from onset.

Timeline

Start
2015-01
Primary completion
2020-06
Completion
2020-06

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Alteplase Protein / enzyme biologic 0.9 mg/kg Intravenous
Subject Tenecteplase Protein / enzyme biologic 0.25 mg/kg Intravenous

Indications